El Renacimiento de la Terapia Asistida con Psicodélicos: Potencial Terapéutico y Retos Éticos de la Psilocibina y el MDMA
Zenodo (CERN European Organization for Nuclear Research) April 11, 2026 preprint DOI: 10.5281/zenodo.19505353 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Topics | MDMA |
| Key findings | Reviews recent phase III trials of psychedelics for PTSD and major depression and the neuronal plasticity mechanisms proposed to underlie their effects. The authors also discuss risks of abuse and contend that specialized psychotherapeutic accompaniment is important to the treatment process. |
Abstract
Tras décadas de prohibición, los psicodélicos regresan a la investigación clínica para tratar el TEPT y la depresión mayor. Este artículo revisa los ensayos fase III recientes y los mecanismos de plasticidad neuronal inducidos. Se analizan los riesgos de abuso y la importancia del acompañamiento psicoterapéutico especializado en el proceso.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |